Stock Events

ORIC Pharmaceuticals 

$10.8
19
-$0.46-4.09% Today

Statistics

Day High
-
Day Low
-
52W High
16.65
52W Low
5.27
Volume
333,455
Avg. Volume
821,976
Mkt Cap
728.16M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

6MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.63
-0.54
-0.46
-0.37
Expected EPS
-0.51
Actual EPS
-0.37

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORIC. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a global pharmaceutical company that competes with ORIC in the oncology sector, particularly in developing treatments for cancer.
Merck &
MRK
Mkt Cap318.55B
Merck is a leading pharmaceutical company that competes directly with ORIC Pharmaceuticals in the cancer treatment space, with a strong focus on innovative oncology drugs.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb is a major competitor in the oncology market, offering a range of cancer treatments that compete with ORIC's product pipeline.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca is a global biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines in oncology, directly competing with ORIC.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences is known for its strong portfolio in oncology and inflammatory diseases, making it a direct competitor to ORIC Pharmaceuticals in cancer treatment research.
AMGEN
AMGN
Mkt Cap177.72B
Amgen is a biotechnology company with a focus on oncology and cardiovascular diseases, competing with ORIC in developing innovative cancer therapies.
Novartis
NVS
Mkt Cap232.42B
Novartis is a global healthcare company that competes with ORIC Pharmaceuticals in the oncology sector, with a wide range of cancer treatments.
Roche
RHHBY
Mkt Cap220.72B
Roche Holding AG is a leading pharmaceutical and diagnostics company, competing with ORIC in the field of oncology through its extensive research and development in cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap814.94B
Eli Lilly and Company is a competitor in the oncology market, with a focus on developing innovative cancer treatments that compete with ORIC's offerings.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals is known for its research in oncology and other areas, making it a competitor to ORIC Pharmaceuticals in developing cancer therapies.

Analyst Ratings

19.17$Average Price Target
The highest estimate is $25.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Show more...
CEO
Jacob Chacko
Employees
102
Country
US
ISIN
US68622P1093
WKN
000A2P208

Listings